Myocardial Angiotensin-Converting Enzyme 2 Protein Expression in Ischemic Heart Failure
Abstract
:1. Introduction
2. Results
2.1. ACE2 Expression in Cardiomyocytes
2.2. ACE2 Expression in Non-Cardiomyocytes
3. Discussion
4. Materials and Methods
4.1. Study Design and Groups
4.2. Immunohistochemistry
4.3. Image Acquisition and Analysis
4.4. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Virani, S.S.; Alonso, A.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Delling, F.N.; et al. Heart disease and stroke statistics—2020 update: A report from the American Heart Association. Circulation 2020, 141, e139–e596. [Google Scholar] [CrossRef] [PubMed]
- Conrad, N.; Judge, A.; Tran, J.; Mohseni, H.; Hedgecott, D.; Crespillo, A.P.; Allison, M.; Hemingway, H.; Cleland, J.G.; McMurray, J.J.V.; et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet 2018, 391, 572–580. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; He, W.; Guo, L.; Zhang, Y.; Li, H.; Han, S.; Shen, D. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. Mol. Med. Rep. 2017, 16, 1973–1981. Available online: https://www.spandidos-publications.com/10.3892/mmr.2017.6848 (accessed on 1 November 2023). [CrossRef] [PubMed]
- Patel, V.B.; Zhong, J.-C.; Grant, M.B.; Oudit, G.Y. Role of the ACE2/angiotensin 1-7 axis of the renin–angiotensin system in heart failure. Circ. Res. 2016, 118, 1313–1326. Available online: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.307708 (accessed on 1 November 2023). [CrossRef] [PubMed]
- Zhu, H.; Zhang, L.; Ma, Y.; Zhai, M.; Xia, L.; Liu, J.; Yu, S.; Duan, W. The role of SARS-CoV-2 target ACE2 in cardiovascular diseases. J. Cell. Mol. Med. 2021, 25, 1342–1349. Available online: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.16239 (accessed on 1 November 2023). [CrossRef]
- Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000, 275, 33238–33243. [Google Scholar] [CrossRef]
- Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002, 277, 14838–14843. [Google Scholar] [CrossRef]
- Nemoto, W.; Ogata, Y.; Nakagawasai, O.; Yaoita, F.; Tadano, T.; Tan-No, K. Angiotensin (1-7) prevents angiotensin II-induced nociceptive behaviour via inhibition of p38 MAPK phosphorylation mediated through spinal Mas receptors in mice. Eur. J. Pain 2014, 18, 1471–1479. [Google Scholar] [CrossRef]
- Rabie, M.A.; Abd El Fattah, M.A.; Nassar, N.N.; El-Abhar, H.S.; Abdallah, D.M. Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF-κB axis. Biochem. Pharmacol. 2018, 151, 126–134. Available online: https://pubmed.ncbi.nlm.nih.gov/29428223/ (accessed on 1 November 2023). [CrossRef]
- Tanno, T.; Tomita, H.; Narita, I.; Kinjo, T.; Nishizaki, K.; Ichikawa, H.; Kimura, Y.; Tanaka, M.; Osanai, T.; Okumura, K. Olmesartan inhibits cardiac hypertrophy in mice overexpressing renin independently of blood pressure: Its beneficial effects on ACE2/Ang(1-7)/Mas axis and NADPH oxidase expression. J. Cardiovasc. Pharmacol. 2016, 67, 503–509. Available online: https://journals.lww.com/cardiovascularpharm/abstract/2016/06000/olmesartan_inhibits_cardiac_hypertrophy_in_mice.7.aspx (accessed on 1 November 2023). [CrossRef]
- Wang, W.; Bodiga, S.; Das, S.K.; Lo, J.; Patel, V.; Oudit, G.Y. Role of ACE2 in diastolic and systolic heart failure. Heart Fail. Rev. 2012, 17, 683–691. Available online: https://link.springer.com/article/10.1007/s10741-011-9259-x (accessed on 1 November 2023). [CrossRef] [PubMed]
- Xiao, L.; Sakagami, H.; Miwa, N. ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: Demon or angel? Viruses 2020, 12, 491. [Google Scholar] [CrossRef] [PubMed]
- Epelman, S.; Tang, W.H.W.; Chen, S.Y.; Lente, F.V.; Francis, G.S.; Sen, S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008, 52, 750–754. Available online: https://pubmed.ncbi.nlm.nih.gov/18718423/ (accessed on 1 November 2023). [CrossRef] [PubMed]
- Epelman, S.; Shrestha, K.; Troughton, R.W.; Francis, G.S.; Sen, S.; Klein, A.L.; Tang, W.H.W. Soluble angiotensin-converting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes. J. Card. Fail. 2009, 15, 565–571. Available online: https://pubmed.ncbi.nlm.nih.gov/19700132/ (accessed on 1 November 2023). [CrossRef] [PubMed]
- Ramchand, J.; Patel, S.K.; Srivastava, P.M.; Farouque, O.; Burrell, L.M. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS ONE 2018, 13, e0198144. Available online: https://pubmed.ncbi.nlm.nih.gov/29897923/ (accessed on 1 November 2023). [CrossRef]
- Ortiz-Pérez, J.T.; Riera, M.; Bosch, X.; Caralt, T.M.; Perea, R.J.; Pascual, J.; Soler, M.J. Role of circulating angiotensin coverting enzyme 2 in left ventricular remodeling following myocardial infarction: A prospective controlled study. PLoS ONE 2013, 22, e61695. Available online: https://pubmed.ncbi.nlm.nih.gov/23630610/ (accessed on 1 November 2023).
- García-Escobar, A.; Jiménez-Valero, S.; Galeote, G.; Jurado-Román, A.; García-Rodríguez, J.; Moreno, R. The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: New insights for heart failure and COVID19. Heart Fail. Rev. 2021, 26, 961–971. Available online: https://pubmed.ncbi.nlm.nih.gov/33404999/ (accessed on 1 November 2023). [CrossRef]
- Hikmet, F.; Méar, L.; Edvinsson, Å.; Micke, P.; Uhlén, M.; Lindskog, C. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 2020, 16, e9610. Available online: https://www.embopress.org/doi/full/10.15252/msb.20209610 (accessed on 1 November 2023). [CrossRef]
- Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454. Available online: https://www.nature.com/articles/nature02145 (accessed on 1 November 2023). [CrossRef]
- Walls, A.C.; Park, Y.-J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020, 181, 281–292. [Google Scholar] [CrossRef]
- Nicin, L.; Abplanalp, W.T.; Mellentin, H.; Kattih, B.; Tombor, L.; John, D.; Schmitto, J.D.; Heineke, J.; Emrich, F.; Arsalan, M.; et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur. Heart J. 2020, 41, 1804–1806. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.; Li, X.; Chen, M.; Feng, Y.; Xiong, C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc. Res. 2020, 116, 1097–1100. [Google Scholar] [CrossRef]
- Tucker, N.R.; Chaffin, M.; Bedi, K.C., Jr.; Papangeli, I.; Akkad, A.-D.; Arduini, A.; Hayat, S.; Eraslan, G.; Muus, C.; Bhattacharyya, R.P.; et al. Myocyte-specific upregulation of ACE2 in cardiovascular disease: Implications for SARS-CoV-2-mediated myocarditis. Circulation 2020, 142, 708–710. Available online: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047911 (accessed on 1 November 2023). [CrossRef] [PubMed]
- Vukusic, K.; Thorsell, A.; Muslimovic, A.; Jonsson, M.; Dellgren, G.; Lindahl, A.; Sandstedt, J.; Hammarsten, O. Overexpression of the SARS-CoV-2 receptor angiotensin converting enzyme 2 in cardiomyocytes of failing hearts. Sci. Rep. 2022, 12, 965. [Google Scholar] [CrossRef] [PubMed]
- Bargehr, J.; Rericha, P.; Petchey, A.; Colzani, M.; Moule, G.; Malgapo, M.C.; Rassl, D.; Tarkin, J.; Mellor, G.; Sampaziotis, F.; et al. Cardiovascular ACE2 receptor expression in patients undergoing heart transplantation. ESC Heart Fail. 2021, 8, 4119–4129. Available online: https://onlinelibrary.wiley.com/doi/10.1002/ehf2.13528 (accessed on 1 November 2023). [CrossRef] [PubMed]
- Heidenreich, P.A.; Bozkurt, B.; Aguilar, D.; Allen, L.A.; Byun, J.J.; Colvin, M.M.; Deswal, A.; Drazner, M.H.; Dunlay, S.M.; Evers, L.R.; et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022, 145, e895–e1032. Available online: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063 (accessed on 1 November 2023). [CrossRef] [PubMed]
- Uhlen, M.; Bandrowski, A.; Carr, S.; Edwards, A.; Ellenberg, J.; Lundberg, E.; Rimm, D.L.; Rodriguez, H.; Hiltke, T.; Snyder, M.; et al. A proposal for validation of antibodies. Nat. Methods 2016, 13, 823–827. Available online: https://www.nature.com/articles/nmeth.3995 (accessed on 1 November 2023). [CrossRef]
- Onabajo, O.O.; Banday, A.R.; Stanifer, M.L.; Yan, W.; Obajemu, A.; Santer, D.M.; Florez-Vargas, O.; Piontkivska, H.; Vargas, J.M.; Prokunina-Olsson, L. Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nat. Genet. 2020, 52, 1283–1293. Available online: https://www.nature.com/articles/s41588-020-00731-9 (accessed on 1 November 2023). [CrossRef]
- Blume, C.; Jackson, C.L.; Spalluto, C.M.; Legebeke, J.; Nazlamova, L.; Conforti, F.; Perotin, J.M.; Frank, M.; Butler, J.; Mennella, V. A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nat. Genet. 2021, 53, 205–214. Available online: https://www.nature.com/articles/s41588-020-00759-x (accessed on 1 November 2023). [CrossRef]
- Williams, T.L.; Strachan, G.; Macrae, R.G.C.; Kuc, R.E.; Nyimanu, D.; Paterson, A.L.; Sinha, S.; Maguire, J.J.; Davenport, A.P. Diferential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS CoV 2 binding sites. Sci. Rep. 2021, 11, 24336. [Google Scholar] [CrossRef]
- Narula, S.; Yusuf, S.; Chong, M.; Ramasundarahettige, C.; Rangarajan, S.; Bangdiwala, S.I.; van Eikels, M.; Leineweber, K.; Wu, A.; Pigeyre, M.; et al. Plasma ACE2 and risk of death or cardiometabolic diseases: A case-cohort analysis. Lancet 2020, 396, 968–976. [Google Scholar] [CrossRef]
- Ohtsuki, M.; Morimoto, S.-I.; Izawa, H.; Ismail, T.F.; Ishibashi-Ueda, H.; Kato, Y.; Horii, T.; Isomura, T.; Suma, H.; Nomura, M.; et al. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int. J. Cardiol. 2010, 145, 333–334. Available online: https://www.sciencedirect.com/science/article/pii/S0167527309016544 (accessed on 1 November 2023). [CrossRef]
- Goulter, A.B.; Goddard, M.J.; Allen, J.C.; Clark, K.L. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004, 2, 19. Available online: https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-2-19 (accessed on 1 November 2023). [CrossRef]
- Qi, J.; Zhou, Y.; Hua, J.; Zhang, L.; Bian, J.; Liu, B.; Zhao, Z.; Jin, S. The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to SARS-CoV-2 infection. Int. J. Environ. Res. Public Health 2021, 18, 284. [Google Scholar] [CrossRef]
- Frantz, S.; Hundertmark, M.J.; Schulz-Menger, J.; Bengel, F.M.; Bauersachs, J. Left ventricular remodelling post-myocardial infarction: Pathophysiology, imaging, and novel therapies. Eur. Heart J. 2022, 43, 2549–2561. [Google Scholar] [CrossRef]
- Burrell, L.M.; Risvanis, J.; Kubota, E.; Dean, R.G.; MacDonald, P.S.; Lu, S.; Tikellis, C.; Grant, S.L.; Lew, R.A.; Smith, A.I.; et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 2005, 26, 369–375. [Google Scholar] [CrossRef]
- Sarkissian, S.D.; Grobe, J.L.; Yuan, L.; Narielwala, D.R.; Walter, G.A.; Katovich, M.J.; Raizada, M.K. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51, 712–718. [Google Scholar] [CrossRef]
- Crackower, M.A.; Sarao, R.; Oudit, G.Y.; Yagil, C.; Kozieradzki, I.; Scanga, S.E.; Oliveira-dos-Santos, A.J.; da Costa, J.; Zhang, L.; Pei, Y.; et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417, 822–828. Available online: https://www.nature.com/articles/nature00786 (accessed on 1 November 2023). [CrossRef]
- Ocaranza, M.P.; Riquelme, J.A.; García, L.; Jalil, J.E.; Chiong, M.; Santos, R.A.S.; Lavandero, S. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 2020, 17, 116–129. Available online: https://www.nature.com/articles/s41569-019-0244-8 (accessed on 1 November 2023). [CrossRef]
- AbdAlla, S.; Lother, H.; Abdel-tawab, A.M.; Quitterer, U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 2001, 276, 39721–39726. Available online: https://www.jbc.org/article/S0021-9258(20)60034-5/fulltext (accessed on 1 November 2023). [CrossRef]
- Bedecs, K.; Elbaz, N.; Sutren, M.; Masson, M.; Susini, C.; Strosberg, A.D.; Nahmias, C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem. J. 1997, 325, 449–454. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1218581/ (accessed on 1 November 2023). [CrossRef]
- Horiuchi, M.; Akishita, M.; Dzau, V.J. Molecular and cellular mechanism of angiotensin II-mediated apoptosis. Endocr. Res. 1998, 24, 307–314. Available online: https://www.tandfonline.com/doi/abs/10.3109/07435809809032610 (accessed on 1 November 2023). [CrossRef]
- Mendoza-Torres, E.; Riquelme, J.A.; Vielma, A.; Sagredo, A.R.; Gabrielli, L.; Bravo-Sagua, R.; Jalil, J.E.; Rothermel, B.A.; Sanchez, G.; Ocaranza, M.P.; et al. Protection of the myocardium against ischemia/reperfusion injury by angiotensin-(1-9) through an AT2R and Akt-dependent mechanism. Pharmacol. Res. 2018, 135, 112–121. Available online: https://www.sciencedirect.com/science/article/abs/pii/S1043661818304717?via%3Dihub (accessed on 1 November 2023). [CrossRef]
- Tao, X.; Fan, J.; Kao, G.; Zhang, X.; Su, L.; Yin, Y.; Zrenner, B. Angiotensin-(1-7) attenuates angiotensin II-induced signalling associated with activation of a tyrosine phosphatase in Sprague-Dawley rats cardiac fibroblasts. Biol. Cell 2014, 106, 182–192. Available online: https://onlinelibrary.wiley.com/doi/10.1111/boc.201400015 (accessed on 1 November 2023). [CrossRef]
- McCollum, L.T.; Gallagher, P.E.; Tallant, E.A. Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides 2012, 34, 380–388. [Google Scholar] [CrossRef]
- Shah, A.; Gul, R.; Yuan, K.; Gao, S.; Oh, Y.-B.; Kim, U.-H.; Kim, S.H. Angiotensin-(1-7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na+/H+ exchanger. Am. J. Physiol. Heart Circ. Physiol. 2010, 298, H1365–H1374. [Google Scholar] [CrossRef]
- Gomes, E.R.; Lara, A.A.; Almeida, P.W.M.; Guimarães, D.; Resende, R.R.; Campagnole-Santos, M.J.; Bader, M.; Santos, R.A.S.; Guatimosim, S. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphatedependent pathway. Hypertension 2010, 55, 153–160. [Google Scholar] [CrossRef]
- Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000, 87, e1–e9. [Google Scholar] [CrossRef]
- He, L.; Mäe, M.A.; Muhl, L.; Sun, Y.; Pietilä, R.; Nahar, K.; Liébanas, E.V.; Fagerlund, M.J.; Oldner, A.; Liu, J.; et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2—Implications for microvascular inflammation and hypercoagulopathy in COVID-19. bioRxiv 2020. [Google Scholar] [CrossRef]
- Avolio, E.; Madeddu, P. Discovering cardiac pericyte biology: From physiopathological mechanisms to potential therapeutic applications in ischemic heart disease. Vascul. Pharmacol. 2016, 86, 53–63. [Google Scholar] [CrossRef]
- Schwinger, R.H.G. Pathophysiology of heart failure. Cardiovasc. Diagn. Ther. 2021, 11, 263–276. Available online: https://pubmed.ncbi.nlm.nih.gov/33708498/ (accessed on 1 November 2023). [CrossRef] [PubMed]
- Bazgir, F.; Nau, J.; Nakhaei-Rad, S.; Amin, E.; Wolf, M.J.; Saucerman, J.J.; Lorenz, K.; Ahmadian, M.R. The microenvironment of the pathogenesis of cardiac hypertrophy. Cells 2023, 12, 1780. [Google Scholar] [CrossRef] [PubMed]
- Sudden Cardiac Death: Report of a WHO Scientific Group; Technical Report Series; World Health Organization: Geneva, Switzerland, 1985; Volume 726, pp. 5–25. Available online: https://iris.who.int/handle/10665/39554#:~:text=Muerte%20cardiaca%20su%CC%81bita%20%3A%20informe%20de%20un%20Grupo,incidence%2C%20causes%2C%20predictive%20factors%2C%20and%20possibilities%20for%20prevention (accessed on 1 November 2023).
- Zeppenfield, K.; Tfelt-Hansen, J.; de Riva, M.; Winkel, B.G.; Behr, E.R.; Blom, N.A.; Charron, P.; Corrado, D.; Dagres, N.; de Chillou, C.; et al. 2022 ESC Guidelines for the management of patients with ventricular arrythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022, 43, 3997–4126. [Google Scholar] [CrossRef] [PubMed]
- Michaud, K.; Basso, C.; d’Amati, G.; Giordano, C.; Kholova, I.; Preston, S.D.; Rizzo, S.; Sabatasso, S.; Sheppard, M.N.; Vink, A.; et al. Diagnosis of myocardial infarction at autopsy: AECVP reappraisal in the light of the current clinical classification. Virchows Arch. 2019, 476, 179–194. [Google Scholar] [CrossRef]
- Torlakovic, E.E.; Nielsen, S.; Francis, G.; Garratt, J.; Gilks, B.; Goldsmith, J.D.; Hornick, J.L.; Hyjek, E.; Ibrahim, M.; Miller, K.; et al. Standardization of positive controls in diagnostic immunohistochemistry: Recommendations from the International Ad Hoc Expert Committee. Appl. Immunohistochem. Mol. Morphol. 2015, 23, 1–18. Available online: https://journals.lww.com/appliedimmunohist/Fulltext/2015/01000/Standardization_of_Positive_Controls_in_Diagnostic.1.aspx (accessed on 1 November 2023). [CrossRef]
- Bankhead, P.; Loughrey, M.B.; Fernández, J.A.; Dombrowski, Y.; McArt, D.G.; Dunne, P.D.; McQuaid, S.; Gray, R.T.; Murray, L.M.; Coleman, H.G.; et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 2017, 7, 16878. Available online: https://www.nature.com/articles/s41598-017-17204-5 (accessed on 1 November 2023). [CrossRef]
Characteristic | Control Group n = 21 | Stage A HF Group n = 25 | Stage B HF Group n = 23 | Stages C/D HF Group n = 34 |
---|---|---|---|---|
Age, mean (SD), years | 50.2 (8.1) | 53.8 (8.0) | 54.4 (7.7) | 56.2 (7.2) |
Sex | Male | Male | Male | Male |
Previous clinical symptoms of HF | No | No | No | Yes |
Treatment with ACE inhibitors (ramipril, perindopril) | No | No | No | Yes (23)/No (11) |
Treatment with angiotensin receptor blockers | No | No | No | No |
Atherosclerotic stenosis ≥ 75% in at least one coronary artery | No | Yes | Yes | Yes |
Old myocardial infarction | No | No | Yes | Yes |
Mass of left ventricular free wall without subepicardial adipose tissue, mean (SD), g | 104.0 (11.9) | 133.4 (21.0) | 155.0 (33.6) | 193.6 (26.7) |
Antibody | Species (Immunogen) | Dilution | Manufacturer (Catalog Number) | PRID | Lot Number |
---|---|---|---|---|---|
ACE2 | Rabbit polyclonal (Synthetic peptide within human ACE2 aa 750 to the C-terminus) | 1:500 | Abcam (ab15348) | AB_301861 | GR3410089-1 |
ACE2 | Rabbit polyclonal (angiotensin-converting enzyme 2 precursor recombinant protein epitope signature tag (PrEST) 1-111aa) | 1:500 | Sigma Aldrich (HPA000288) | AB_1078160 | 000013837 |
αSMA | Mouse monoclonal, cl 1A4 (N-terminal synthetic decapeptide of αSMA) | 1:100 | Agilent Dako (M085101-2) | AB_2223500 | 41480058 |
CD31 | Mouse monoclonal, cl JC70A (the epitope recognized was found to be within the extracellular domain 1) | 1:100 | Agilent Dako (M082301-2) | AB_2114471 | 41495396 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Siratavičiūtė, V.; Pangonytė, D.; Utkienė, L.; Jusienė, L.; Marcinkevičienė, J.; Stanionienė, Z.; Radikė, R. Myocardial Angiotensin-Converting Enzyme 2 Protein Expression in Ischemic Heart Failure. Int. J. Mol. Sci. 2023, 24, 17145. https://doi.org/10.3390/ijms242417145
Siratavičiūtė V, Pangonytė D, Utkienė L, Jusienė L, Marcinkevičienė J, Stanionienė Z, Radikė R. Myocardial Angiotensin-Converting Enzyme 2 Protein Expression in Ischemic Heart Failure. International Journal of Molecular Sciences. 2023; 24(24):17145. https://doi.org/10.3390/ijms242417145
Chicago/Turabian StyleSiratavičiūtė, Vitalija, Dalia Pangonytė, Lina Utkienė, Lina Jusienė, Jolanta Marcinkevičienė, Zita Stanionienė, and Reda Radikė. 2023. "Myocardial Angiotensin-Converting Enzyme 2 Protein Expression in Ischemic Heart Failure" International Journal of Molecular Sciences 24, no. 24: 17145. https://doi.org/10.3390/ijms242417145